The MP2PRT program is a Cancer Moonshot Research Initiative supporting the retrospective characterization and analysis of biospecimens collected from NCI-sponsored trials. The objectives of this program are to: (i) perform next-generation sequencing on archived tumor and normal biospecimens collected from patients enrolled on completed clinical trials with available outcome data and (ii) analyze the molecular characterization and clinical data following hypotheses developed by teams of clinicians and scientists associated with the NCI-sponsored trials.
These analyses will broaden the scientific community’s understanding of the molecular mechanisms that contribute to tumor response and resistance to treatment and may help guide ongoing and future clinical trials.
The Biospecimen Research Group manages the MP2PRT program and oversees its support of eight individual research studies that were selected by the NCI Cancer Therapy Evaluation Program (CTEP). The findings from each of these studies will be published, with all molecular characterization data made publicly available.
The first study, titled “Genetic changes associated with relapse in favorably histology Wilms tumor: A Children’s Oncology Group AREN03B2 study,” has been published in Cell Reports Medicine, and all data is available through the NCI Genomic Data Commons.
For any further information related to the Molecular Profiling To Predict Response To Treatment (MP2PRT) Program, please feel free to contact Christopher Szot, Ph.D., at BRGSupport@nih.gov.